Publication | Closed Access

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

Egfr Driver MutationsSclerostinBone Morphogenic ProteinMedicineMolecular BiologySequential Liquid BiopsiesMolecular DiagnosticsCell BiologyTumor BiologyEgfr Amplification